Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet

Mika H Martikainen¹, Markku Päivärinta¹, Satu Jääskeläinen², Kari Majamaa³

¹ Department of Neurology
² Department of Clinical Neurophysiology, University of Turku and Turku University Hospital, Turku
³ University of Oulu, Department of Clinical Medicine and Neurology and Oulu University Hospital, Department of Neurology, Oulu, Finland

Received June 29, 2012; Accepted October 22, 2012

ABSTRACT – Epilepsy is a common manifestation of mitochondrial disease associated with mutations of the mitochondrial polymerase γ (POLG). Prognosis of mitochondrial epilepsy is often poor and there are few reports of successful treatment of POLG-related epilepsy. We describe a 26-year-old woman who experienced severe headache during a three-day period, followed by symptoms of visual flashing, speech difficulty, and generalised seizures. EEG recording showed non-convulsive status epilepticus (left occipital area) and brain MRI revealed parieto-occipital T2-hyperintensities. Visual aura and aphasia persisted despite antiepileptic medication with phenytoin, oxcarbazepine, and levetiracetam. Mitochondrial disorder was clinically suspected and a homozygous c.2243G>C mutation (p.Trp748Ser) was discovered in the POLG1 gene. The patient was then set on a low glycaemic index treatment (LGIT) variant of the ketogenic diet, after which the headaches, aphasia, and visual aura progressively improved and disappeared. She returned home two weeks after onset of symptoms and has not had further seizures. She continues to receive levetiracetam monotherapy and LGIT. We conclude that, at least for this patient, the combination of three antiepileptic drugs and LGIT is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy.

Key words: epilepsy, ketogenic diet, low glycemic index treatment, mitochondrial disease, POLG

Epilepsy is a prevalent feature of disease related to mutations in the gene encoding the catalytic subunit of human mitochondrial DNA polymerase γ, POLG (Tzoulis et al., 2006). Prognosis of mitochondrial epilepsy is often poor and there are only few reports of successful treatment of POLG-related epilepsy. The ketogenic diet (KD) is used as treatment
Treatment of POLG-related mitochondrial epilepsy for intractable epilepsy and beneficial effect of KD in severe POLG-related epilepsy in children has been previously reported (Joshi *et al.*, 2009). Here, we describe successful treatment of a 26-year-old woman with severe episodes of POLG-associated epilepsy (non-convulsive status epilepticus; NCSE) using phenytoin, oxcarbazepine, and levetiracetam medications with a low glycaemic index treatment (LGIT); a modified KD.

**Case report**

The patient was investigated as a result of severe headaches at the age of 22 years. Brain MRI revealed non-specific white matter T2-hyperintensities in cerebellar hemispheres. Clinically, horizontal nystagmus and slight problems with balance were noted. The diagnosis of multiple sclerosis was entertained, but not supported by her medical history and CSF examination. No further investigations were performed. At age 26 years, she experienced a severe headache during a 3-day period. On day 4 after symptom onset, she presented to the emergency unit after having two generalised seizures. She also had symptoms of visual flashing, fluctuating visual blurring and field defects, and speech difficulty. There was no previous history of such symptoms. At presentation, she was slightly confused, but the neurological examination was otherwise normal. No signs of meningeal irritation were noted. White cell count, myoglobin, and creatine kinase values were elevated, but other routine investigations including CSF were normal. Head CT was normal. Meningoencephalitis or cerebral sinus thrombosis were not considered likely. The patient was admitted to the neurological ward for follow-up, but no antiepileptic medication was started.

On day 5, the patient had yet another seizure and intravenous phenytoin was initiated. She had severe headache with persistent visual aura, despite treatment with conventional analgesics, and a right homonymous hemianopia. She had word finding difficulties but normal comprehension and she was not able to perform simple numerical tasks (e.g. counting down from 100). On day 6, EEG revealed slight slowing-down of background and continuous epileptiform polyspike and slow-wave complexes occurring pseudo-periodically at 0.5 to 2-second intervals within the left temporo-parieto-occipital region, with negative maximum at the occipital electrode O1. These complexes were very similar to the rhythmic, high-amplitude, delta activity with polyspikes (RHADS) previously reported in children with POLG-related status epilepticus (Wolf *et al.*, 2009); however, in this adult patient, the amplitude of the delta waves only reached 130 µV (figure 1). The clinical condition and

---

**Figure 1.** Twenty-three-channel EEG recording obtained during non-convulsive status epilepticus (day 6). Continuous, quasi-rhythmic polyspike-and-delta wave activity was present within the left occipital region (maximum at O1 electrode). Recording was performed with NicoletOne EEG (Nervus device, Cephalon Ltd., Nørresundby, Denmark), Electrocap with Ag-AgCl-electrodes, and standard international 10/20 electrode placement. The space between each vertical line represents one second and a bar of 100 µV is depicted above the EOG channel on the right-hand side.
EEG findings were compatible with NCSE. On the same day, brain MRI revealed new T2-hyperintense, oedemic lesions in the left thalamus and left parieto-occipital region (figure 2). Oxcarbazepine and levetiracetam were added to antiepileptic medication. POLG-related mitochondrial disorder was now suspected based on clinical symptoms as well as EEG and MRI findings (Uusimaa et al., 2008; Wolf et al., 2009) and genetic testing was requested. On day 7, she was given LGIT (for details, see Pfeifer and Thiele [2005]) which has been reported to be useful in patients with intractable epilepsy (Kossoff and Hartman, 2012; Pfeifer and Thiele, 2005). The diet was well tolerated with no significant side effects. The patient’s condition improved such that the headaches, aphasia, and visual aura gradually disappeared during the following four days. There were no further seizures. At discharge on day 12, she still had homonymous right-sided visual field defect, which resolved slowly. Two months later, the visual fields were normal. During the follow-up, the patient did not have further seizures. Phenytin and oxcarbazepine were gradually discontinued and she continues to receive levetiracetam monotherapy and LGIT. Genetic testing revealed a homozygous c.2243G>C mutation of the POLG1 gene leading to p.Trp748Ser.

Discussion

The ketogenic diet, including LGIT, has several plausible anticonvulsant mechanisms, such as increased energy production and increased γ-aminobutyric acid (GABA) synthesis in the brain (Bough and Rho, 2007; Kossoff and Hartman, 2012). In addition, recent animal study data suggest that a ketogenic diet may have beneficial effects for mitochondrial disorders (AHola-Erkkilä et al., 2010). POLG-related mitochondrial disease is common in the population, e.g., in Finland, the carrier frequency of the p.Trp748Ser allele is estimated to be 1:125 (Hakonen et al., 2005). In POLG-related mitochondrial epilepsy, progression to status epilepticus is common and this condition may be highly resistant to treatment (Tzoulis et al., 2006). Benefit of magnesium treatment has recently been reported in two patients with refractory status epilepticus and another homozygous POLG1 mutation (p.Ala467Thr) (Visser et al., 2011). Magnesium treatment was, however, not applied for the treatment of the patient reported here. We conclude that the combination of phenytin, oxcarbazepine, levetiracetam, and LGIT was effective and well tolerated in a patient with severe episodes of POLG-related mitochondrial epilepsy manifesting as NCSE. We suggest that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.
Disclosures.
None of the authors has any conflict of interests to disclose.

References


